| Popis: |
Significant advances during the last few years continue to suggest the potential for plant-based mucosal immunotherapies. The diversity of technologies for transformation and the increasing efficiency of expressing recombinant proteins in plants provide a variety of manufacturing platforms to choose from. Despite these technological advances and a large body of preclinical trial data using animal models, there are currently no commercially marketed, plant-based mucosal immunotherapeutics. This review focuses on the actual and perceived challenges for future development and commercialization of such products. |
